Acute leukemia patients treated with common therapy have increased risk for heart failure
(University of Pennsylvania School of Medicine) Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heightened risk of heart failure -- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine. To help identify a patient's risk for heart failure following the treatment, researchers developed a risk score (0 to 21) based on clinical and echographic variables.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Heart | Heart Failure | Leukemia | Study | University of Pennsylvania